Physician profile
Andra E Batlin
NPI 1801816343
$2,368.16
in general payments reported to CMS, 2019-2025
29 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $82.49 · 2021: $409 · 2022: $481 · 2023: $679 · 2024: $229 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $355.50 | 2019-2025 | Breztri, Airsupra, Andexxa |
| Lilly USA, LLC | $225.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $154.75 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $153.26 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $151.23 | 2019-2025 | Veozah |
| Pfizer INC. | $138.94 | 2021-2023 | |
| Abbvie INC. | $120.52 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $117.95 | 2021 | |
| Abbott Laboratories | $114.11 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $93.65 | 2020-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $82.28 | 2022-2023 | Arexvy |
| Merck Sharp & Dohme LLC | $72.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.88 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.10 | 2022-2025 | Jardiance |
| Agios Pharmaceuticals, INC. | $55.09 | 2024-2025 | Pyrukynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $54.26 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.76 | 2021-2022 | |
| Esperion Therapeutics, INC. | $42.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.61 | 2021-2022 | |
| Ibsa Pharma INC. | $35.57 | 2022 | |
| Bausch Health US, LLC | $35.15 | 2022 | |
| Allergan, INC. | $24.75 | 2020 | |
| Nabriva Therapeutics, Plc | $23.05 | 2020 | |
| Abiomed | $22.55 | 2024 | Impella |
| Avanir Pharmaceuticals, INC. | $21.53 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.20 | 2025 | Zoryve |
| Lundbeck LLC | $18.62 | 2023 | Rexulti |
| Hikma Pharmaceuticals USA | $13.68 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.55 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andra Batlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.